page contents

Just How Bad Is Alkermes' Depression Drug Setback?

[unable to retrieve full-text content]

Alkermes Plc NASDAQ ALKS is already marketing drugs for central nervous system disorders and generated nearly 250 million in revenue last quarter Its plans to launch a new drug treating depression however suffered a big setback this month when the FDA s advisory
Latest Articles in

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.